COGT
Cogent Biosciences, Inc.
Stock
$31.02−0.57 (−1.80%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $792M | $901M | $287M | $266M | $259M | $220M | $242M | $37M | $79M | $41M |
| Current assets | $805M | $910M | $296M | $271M | $265M | $223M | $245M | $41M | $81M | $42M |
| Total assets | $835M | $938M | $328M | $313M | $301M | $232M | $251M | $49M | $86M | $49M |
| Current liabilities | $59M | $64M | $56M | $38M | $27M | $17M | $13M | $13M | $25M | $11M |
| Long-term debt | $223M | $223M | $0 | — | — | — | — | — | — | — |
| Total liabilities | $302M | $301M | $72M | $56M | $45M | $18M | $16M | $18M | $26M | $21M |
| Shareholders' equity | $532M | $636M | $256M | $258M | $256M | $214M | $235M | $32M | $60M | −$49M |
| Shares outstanding | 173.5M | 162.3M | 113.9M | 103.9M | 69.9M | 45.8M | 37.2M | 7.7M | 7.5M | — |
| Current ratio | 13.57 | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.79 |